Preference of Genetic Polymorphism and Pharmacokinetics
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01658371 |
Recruitment Status
:
Completed
First Posted
: August 7, 2012
Last Update Posted
: August 7, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
HIV |
Study Type : | Observational |
Actual Enrollment : | 100 participants |
Time Perspective: | Cross-Sectional |
Official Title: | Preference of CYP450 2B6 516 G>T Polymorphism and Pharmacokinetics of Plasma Efavirenz in A Group of HIV Infected Southern Chinese |
Study Start Date : | May 2008 |
Actual Primary Completion Date : | December 2009 |
Actual Study Completion Date : | June 2010 |

Group/Cohort |
---|
efavirenz
HIV patients on efavirenz
|
- pharmacokinetics [ Time Frame: 24 hour ]This includes plasma concentration of drugs in relation to time, in different genotypes
- genotypes frequency [ Time Frame: 1 year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Southern Chinese HIV patients on efavirenz
Exclusion Criteria:
- Refuse to sign consent, HIV patients not on efavirenz

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01658371
China, Hong Kong | |
The Chinese University of Hong Kong | |
Hong Kong, Hong Kong, China |
Principal Investigator: | S S Lee, Professor | Chinese University of Hong Kong |
Responsible Party: | To Kin Wang, Specialist, Chinese University of Hong Kong |
ClinicalTrials.gov Identifier: | NCT01658371 History of Changes |
Other Study ID Numbers: |
CRE-2008.180 |
First Posted: | August 7, 2012 Key Record Dates |
Last Update Posted: | August 7, 2012 |
Last Verified: | August 2012 |
Keywords provided by To Kin Wang, Chinese University of Hong Kong:
HIV |
Additional relevant MeSH terms:
Efavirenz Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Antiviral Agents |
Anti-Infective Agents Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 CYP2B6 Inducers Cytochrome P-450 Enzyme Inducers Cytochrome P-450 CYP3A Inducers |